Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Benitec Biopharma (BNTC) Financials

Benitec Biopharma logo
$11.38 +0.39 (+3.51%)
Closing price 03:59 PM Eastern
Extended Trading
$11.37 -0.01 (-0.05%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Benitec Biopharma

Annual Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 6/30/2022 6/30/2023 6/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 -18 -20 -22
Consolidated Net Income / (Loss)		 -18 -20 -22
Net Income / (Loss) Continuing Operations		 -18 -20 -22
Total Pre-Tax Income 		-18 -20 -22
Total Operating Income		 -18 -19 -22
Total Gross Profit		 0.07 0.08 0.00
Total Revenue		 0.07 0.08 0.00
Operating Revenue		 0.07 0.08 0.00
Total Cost of Revenue		 0.00 0.00 0.00
Total Operating Expenses		 18 19 22
Selling, General & Admin Expense		 6.65 6.38 6.99
Research & Development Expense		 11 13 16
Other Operating Expenses / (Income)		 0.01 0.00 -0.11
Total Other Income / (Expense), net		 -0.35 -0.48 0.74
Interest & Investment Income		 -0.03 -0.03 0.90
Other Income / (Expense), net		 -0.32 -0.45 -0.17
Preferred Stock Dividends Declared		 - - 0.62
Basic Earnings per Share		 ($37.88) ($14.12) ($5.51)
Weighted Average Basic Shares Outstanding		 480.69K 1.39M 4.06M
Diluted Earnings per Share		 ($37.88) ($14.12) ($5.51)
Weighted Average Diluted Shares Outstanding		 480.69K 1.39M 4.06M
Weighted Average Basic & Diluted Shares Outstanding		 8.17M 2.55M 10.56M

Quarterly Income Statements for Benitec Biopharma

This table shows Benitec Biopharma's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 3/31/2022 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2024 3/31/2024 6/30/2024 9/30/2024
Net Income / (Loss) Attributable to Common Shareholders		 -3.28 -5.07 -5.09 -5.41 -4.40 -4.66 -6.57 -7.36 -4.28 -5.34 -5.06
Consolidated Net Income / (Loss)		 -3.28 -5.07 -5.09 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06
Net Income / (Loss) Continuing Operations		 -3.28 -5.07 -5.09 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06
Total Pre-Tax Income 		-3.28 -5.07 -5.09 -5.41 -4.40 -4.66 -5.95 -7.36 -4.28 -4.72 -5.06
Total Operating Income		 -3.46 -4.74 -4.58 -5.61 -4.34 -4.55 -5.87 -8.61 -4.14 -5.55 -5.79
Total Gross Profit		 0.05 - 0.00 0.01 0.05 0.01 0.00 0.00 0.00 - 0.00
Total Revenue		 0.05 - 0.00 0.01 0.05 0.01 0.00 0.00 0.00 - 0.00
Operating Revenue		 0.05 - - 0.01 0.05 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 3.51 4.74 4.58 5.62 4.40 4.56 5.87 8.61 4.14 5.55 5.79
Selling, General & Admin Expense		 1.34 1.55 1.92 1.86 1.23 1.37 1.55 3.54 1.58 2.04 2.21
Research & Development Expense		 2.17 3.18 2.66 3.76 3.17 3.19 4.43 5.07 2.57 3.51 3.59
Other Operating Expenses / (Income)		 - - 0.00 0.00 0.00 - -0.11 0.00 -0.00 - 0.00
Total Other Income / (Expense), net		 0.19 -0.33 -0.51 0.20 -0.06 -0.11 -0.08 1.25 -0.14 0.83 0.73
Interest & Investment Income		 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 0.82 -0.00 0.92 0.60
Other Income / (Expense), net		 0.20 -0.32 -0.50 0.21 -0.05 -0.10 -0.07 -0.33 -0.13 -0.09 0.13
Preferred Stock Dividends Declared		 - - - - - - 0.62 0.00 - - 0.00
Basic Earnings per Share		 ($0.40) ($10.54) ($7.98) ($3.34) ($2.67) ($3.36) ($3.05) ($0.33) ($1.64) ($1.31) ($0.48)
Weighted Average Basic Shares Outstanding		 8.17M 480.69K 638.57K 1.62M 1.65M 1.39M 2.16M 22.08M 2.62M 4.06M 10.64M
Diluted Earnings per Share		 ($0.40) ($10.54) ($7.98) ($3.34) ($2.67) ($3.36) ($3.05) ($0.33) ($1.64) ($1.31) ($0.48)
Weighted Average Diluted Shares Outstanding		 8.17M 480.69K 638.57K 1.62M 1.65M 1.39M 2.16M 22.08M 2.62M 4.06M 10.64M
Weighted Average Basic & Diluted Shares Outstanding		 8.17M 8.17M 27.98M 27.98M 27.98M 2.55M 2.57M 23.45M 9.37M 10.56M 23.22M

Annual Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 6/30/2022 6/30/2023 6/30/2024
Net Change in Cash & Equivalents		 -16 -1.59 48
Net Cash From Operating Activities		 -16 -18 -19
Net Cash From Continuing Operating Activities		 -16 -18 -19
Net Income / (Loss) Continuing Operations		 -18 -20 -22
Consolidated Net Income / (Loss)		 -18 -20 -22
Depreciation Expense		 0.17 0.14 0.09
Amortization Expense		 0.23 0.25 0.26
Non-Cash Adjustments To Reconcile Net Income		 0.88 0.46 0.83
Changes in Operating Assets and Liabilities, net		 1.04 0.71 1.17
Net Cash From Investing Activities		 -0.01 -0.00 -0.18
Net Cash From Continuing Investing Activities		 -0.01 -0.00 -0.18
Purchase of Property, Plant & Equipment		 -0.01 -0.00 -0.18
Net Cash From Financing Activities		 0.00 16 68
Net Cash From Continuing Financing Activities		 0.00 16 68
Repurchase of Common Equity		 0.00 -1.87 -5.89
Issuance of Common Equity		 0.00 18 74
Effect of Exchange Rate Changes		 0.20 0.41 -0.01

Quarterly Cash Flow Statements for Benitec Biopharma

This table details how cash moves in and out of Benitec Biopharma's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 3/31/2022 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024
Net Change in Cash & Equivalents		 -3.70 -4.57 12 -6.00 -3.99 -4.08 23 -5.49 -6.23 37 17
Net Cash From Operating Activities		 -3.42 -4.86 -4.05 -5.84 -4.03 -4.10 -4.58 -5.37 -6.17 -3.29 -4.59
Net Cash From Continuing Operating Activities		 -3.42 -4.86 -4.05 -5.84 -4.03 -4.10 -4.58 -5.37 -6.17 -3.29 -4.59
Net Income / (Loss) Continuing Operations		 -3.27 -5.07 -5.09 -5.41 -4.40 -4.66 -5.95 -6.80 -4.28 -4.72 -5.06
Consolidated Net Income / (Loss)		 -3.27 -5.07 -5.09 -5.41 -4.40 -4.66 -5.95 -6.80 -4.28 -4.72 -5.06
Depreciation Expense		 0.05 0.01 0.04 0.04 0.03 0.02 0.02 0.02 0.03 0.03 0.03
Amortization Expense		 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.07 0.07 0.07
Non-Cash Adjustments To Reconcile Net Income		 0.06 0.31 0.24 -0.11 0.01 0.31 0.09 0.09 0.19 0.45 0.44
Changes in Operating Assets and Liabilities, net		 -0.32 -0.16 0.71 -0.43 0.26 0.17 1.20 1.26 -2.17 0.88 -0.05
Net Cash From Investing Activities		 - -0.01 0.00 - - -0.00 0.00 - -0.18 - 0.00
Net Cash From Continuing Investing Activities		 - -0.01 0.00 - - -0.00 0.00 - -0.18 - 0.00
Net Cash From Financing Activities		 - - 16 - - - 28 0.04 - 40 22
Net Cash From Continuing Financing Activities		 - - 16 - - - 28 0.04 - 40 22
Repurchase of Common Equity		 - - -1.87 - - - -2.96 - - -2.93 0.00
Other Financing Activities, net		 - - - - - - 31 0.04 - - 22
Effect of Exchange Rate Changes		 -0.28 0.30 0.50 -0.15 0.04 0.02 0.05 -0.16 0.12 -0.01 -0.09

Annual Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 6/30/2022 6/30/2023 6/30/2024
Total Assets		 5.97 4.46 52
Total Current Assets		 4.82 3.73 52
Cash & Equivalents		 4.06 2.48 51
Restricted Cash		 0.01 0.01 0.06
Accounts Receivable		 0.00 0.06 0.23
Prepaid Expenses		 0.74 1.18 0.52
Plant, Property, & Equipment, net		 0.22 0.09 0.18
Total Noncurrent Assets		 0.93 0.65 0.36
Other Noncurrent Operating Assets		 0.93 0.65 0.36
Total Liabilities & Shareholders' Equity		 5.97 4.46 52
Total Liabilities		 3.09 4.26 4.96
Total Current Liabilities		 2.53 3.98 4.92
Accounts Payable		 1.88 3.23 4.17
Current Employee Benefit Liabilities		 0.40 0.47 0.48
Other Current Liabilities		 0.25 0.28 0.28
Total Noncurrent Liabilities		 0.56 0.28 0.04
Noncurrent Employee Benefit Liabilities		 - 0.00 0.04
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.88 0.20 47
Total Preferred & Common Equity		 2.88 0.20 47
Preferred Stock		 - - 0.00
Total Common Equity		 2.88 0.20 47
Common Stock		 152 169 238
Retained Earnings		 -148 -168 -190
Accumulated Other Comprehensive Income / (Loss)		 -1.25 -0.83 -0.89

Quarterly Balance Sheets for Benitec Biopharma

This table presents Benitec Biopharma's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 3/31/2022 9/30/2022 12/31/2022 3/31/2023 9/30/2023 12/31/2024 3/31/2024 9/30/2024
Total Assets		 10 18 12 8.22 27 79 15 69
Total Current Assets		 8.84 17 11 7.40 26 79 14 68
Cash & Equivalents		 8.63 17 11 6.55 26 78 14 68
Restricted Cash		 - 0.01 0.01 0.01 0.01 0.06 0.01 0.06
Accounts Receivable		 0.01 0.00 0.07 0.06 0.05 0.00 0.05 0.00
Prepaid Expenses		 0.21 0.53 0.36 0.77 0.48 0.37 0.16 0.43
Plant, Property, & Equipment, net		 0.21 0.18 0.14 0.11 0.07 0.15 0.20 0.15
Total Noncurrent Assets		 1.01 0.86 0.79 0.72 0.57 0.20 0.43 0.29
Other Noncurrent Operating Assets		 1.01 0.86 0.79 0.72 0.57 0.20 0.43 0.29
Total Liabilities & Shareholders' Equity		 10 18 12 8.22 27 79 15 69
Total Liabilities		 2.54 3.50 2.91 3.51 4.75 3.13 3.50 4.59
Total Current Liabilities		 1.91 3.01 2.49 3.15 4.53 3.09 3.44 4.55
Accounts Payable		 1.32 2.37 1.83 2.46 3.79 2.42 2.63 3.85
Current Employee Benefit Liabilities		 0.36 0.39 0.40 0.43 0.46 0.54 0.52 0.50
Other Current Liabilities		 0.23 0.26 0.26 0.27 0.28 0.14 0.29 0.21
Total Noncurrent Liabilities		 0.64 0.49 0.42 0.35 0.21 0.04 0.06 0.04
Noncurrent Employee Benefit Liabilities		 - - - - - 0.04 - 0.04
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 7.52 15 8.99 4.71 22 76 12 64
Total Preferred & Common Equity		 7.52 15 8.99 4.71 22 76 12 64
Total Common Equity		 7.52 15 8.99 4.71 22 76 12 64
Common Stock		 152 169 169 169 197 279 197 260
Retained Earnings		 -143 -153 -159 -163 -174 -203 -185 -195
Accumulated Other Comprehensive Income / (Loss)		 -1.51 -0.74 -0.90 -0.85 -0.78 -0.69 -0.84 -0.99

Annual Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric 2022 2023 2024
Period end date 6/30/2022 6/30/2023 6/30/2024
Growth Metrics		 - - -
Revenue Growth		 23.73% 2.74% -100.00%
EBITDA Growth		 -32.20% -7.67% -16.52%
EBIT Growth		 -30.99% -7.44% -16.01%
NOPAT Growth		 -31.32% -6.87% -17.87%
Net Income Growth		 -31.16% -7.44% -11.19%
EPS Growth		 -31.16% -7.44% 60.98%
Operating Cash Flow Growth		 -23.90% -13.29% -7.72%
Free Cash Flow Firm Growth		 -19.04% -10.70% -17.02%
Invested Capital Growth		 -628.32% -91.62% -60.88%
Revenue Q/Q Growth		 0.00% 10.29% -100.00%
EBITDA Q/Q Growth		 -7.26% 2.17% -4.59%
EBIT Q/Q Growth		 -6.84% 2.03% -4.56%
NOPAT Q/Q Growth		 -5.20% 0.97% -4.64%
Net Income Q/Q Growth		 -6.21% 2.03% -0.27%
EPS Q/Q Growth		 -6.21% 2.03% 33.53%
Operating Cash Flow Q/Q Growth		 1.86% 4.05% 3.97%
Free Cash Flow Firm Q/Q Growth		 6.34% 3.79% -0.77%
Invested Capital Q/Q Growth		 -7.57% -23.54% -38.59%
Profitability Metrics		 - - -
Gross Margin		 100.00% 100.00% 0.00%
EBITDA Margin		 -24,361.64% -25,530.67% 0.00%
Operating Margin		 -24,457.53% -25,441.33% 0.00%
EBIT Margin		 -24,898.63% -26,038.67% 0.00%
Profit (Net Income) Margin		 -24,942.47% -26,082.67% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 100.18% 100.17% 96.01%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -159.08% -1,268.61% -91.68%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -132.90% -374.23% 0.00%
Return on Assets (ROA)		 -133.14% -374.86% 0.00%
Return on Common Equity (ROCE)		 -159.08% -1,268.61% -91.68%
Return on Equity Simple (ROE_SIMPLE)		 -631.78% 0.00% -46.04%
Net Operating Profit after Tax (NOPAT)		 -12 -13 -16
NOPAT Margin		 -17,120.27% -17,808.93% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -47.86% -189.01% -22.49%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 9,104.11% 8,509.33% 0.00%
R&D to Revenue		 15,441.10% 17,032.00% 0.00%
Operating Expenses to Revenue		 24,557.53% 25,541.33% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -20 -23
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -19 -22
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 3.29 33.04 1.39
Price to Tangible Book Value (P/TBV)		 3.29 33.04 1.39
Price to Revenue (P/Rev)		 129.85 88.98 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 74.02 55.78 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.04 -2.13 -1.13
Leverage Ratio		 1.19 3.38 1.19
Compound Leverage Factor		 1.20 3.39 1.15
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 -42.50 -66.20 2.46
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 1.90 0.94 10.49
Quick Ratio		 1.61 0.64 10.38
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -11 -12 -14
Operating Cash Flow to CapEx		 -122,300.00% -1,801,200.00% -10,839.66%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.01 0.01 0.00
Accounts Receivable Turnover		 5.21 2.59 0.00
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.24 0.49 0.00
Accounts Payable Turnover		 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 70.00 141.13 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 70.00 141.13 0.00
Capital & Investment Metrics		 - - -
Invested Capital		 -1.19 -2.29 -3.68
Invested Capital Turnover		 -0.15 -0.04 0.00
Increase / (Decrease) in Invested Capital		 -1.42 -1.09 -1.39
Enterprise Value (EV)		 5.40 4.18 15
Market Capitalization		 9.48 6.67 65
Book Value per Share		 $0.35 $0.01 $5.04
Tangible Book Value per Share		 $0.35 $0.01 $5.04
Total Capital		 2.88 0.20 47
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -4.08 -2.49 -51
Capital Expenditures (CapEx)		 0.01 0.00 0.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.79 -2.74 -4.18
Debt-free Net Working Capital (DFNWC)		 2.29 -0.25 47
Net Working Capital (NWC)		 2.29 -0.25 47
Net Nonoperating Expense (NNE)		 5.71 6.21 6.01
Net Nonoperating Obligations (NNO)		 -4.08 -2.49 -51
Total Depreciation and Amortization (D&A)		 0.39 0.38 0.34
Debt-free, Cash-free Net Working Capital to Revenue		 -2,449.32% -3,652.00% 0.00%
Debt-free Net Working Capital to Revenue		 3,134.25% -332.00% 0.00%
Net Working Capital to Revenue		 3,134.25% -332.00% 0.00%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($37.91) ($14.12) ($5.51)
Adjusted Weighted Average Basic Shares Outstanding		 480.69K 1.39M 4.06M
Adjusted Diluted Earnings per Share		 ($37.91) ($14.12) ($5.51)
Adjusted Weighted Average Diluted Shares Outstanding		 480.69K 1.39M 4.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 480.69K 2.55M 10.56M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -13 -16
Normalized NOPAT Margin		 -17,120.27% -17,808.93% 0.00%
Pre Tax Income Margin		 -24,942.47% -26,082.67% 0.00%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -9.55% -27.09%

Quarterly Metrics And Ratios for Benitec Biopharma

This table displays calculated financial ratios and metrics derived from Benitec Biopharma's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 3/31/2022 6/30/2022 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2024 3/31/2024 6/30/2024 9/30/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 2,300.00% 0.00% 0.00% -44.00% 12.50% 0.00% 0.00% -100.00% -100.00% 0.00% 0.00%
EBITDA Growth		 19.37% -31.73% -0.81% -12.84% -36.37% 8.51% -17.74% -67.25% 2.61% -21.45% 5.01%
EBIT Growth		 18.84% -29.90% -0.79% -12.31% -34.46% 7.99% -16.99% -65.57% 2.62% -21.21% 4.79%
NOPAT Growth		 8.78% 13.96% 5.02% -16.03% -25.46% 3.95% -28.25% -53.48% 4.61% -21.93% 1.41%
Net Income Growth		 16.22% -26.58% -0.95% -12.24% -34.26% 8.01% -16.91% -35.96% 2.68% -1.27% 15.03%
EPS Growth		 51.22% -26.58% -0.95% -12.24% -34.26% 8.01% 61.78% 90.12% 38.58% 61.01% 84.26%
Operating Cash Flow Growth		 -72.05% 5.86% 5.45% -74.73% -17.74% 15.65% -13.15% 8.18% -53.09% 19.58% -0.20%
Free Cash Flow Firm Growth		 -48.39% 47.96% 46.29% -202.62% 3.09% -10.29% -62.52% -34.09% 8.80% -19.11% -57.37%
Invested Capital Growth		 -4.91% -628.32% -667.46% -4.29% -66.85% -91.62% -84.54% -54.40% -43.41% -60.88% -4.37%
Revenue Q/Q Growth		 92.00% 0.00% 0.00% 0.00% 285.71% -87.04% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 32.91% -58.49% 0.24% -6.38% 18.92% -6.33% -28.39% -51.11% 37.65% -32.59% -0.41%
EBIT Q/Q Growth		 32.12% -54.89% -0.53% -6.25% 18.73% -5.99% -27.83% -50.37% 37.06% -31.93% -0.41%
NOPAT Q/Q Growth		 28.44% -36.91% 3.31% -22.49% 22.62% -4.81% -29.10% -46.58% 40.22% -33.98% -4.38%
Net Income Q/Q Growth		 32.07% -54.72% -0.51% -6.24% 18.74% -6.00% -27.74% -23.56% 37.06% -10.31% -7.18%
EPS Q/Q Growth		 32.20% -54.72% -0.51% -6.24% 18.74% -6.00% 9.23% 89.18% 37.88% 20.12% 63.36%
Operating Cash Flow Q/Q Growth		 -2.33% -41.88% 16.68% -44.45% 31.05% -1.64% -11.77% -17.22% -14.97% 46.61% -39.27%
Free Cash Flow Firm Q/Q Growth		 -85.66% 20.00% 19.62% -153.48% 40.55% 8.96% -18.45% -109.14% -40.78% -18.90% -56.50%
Invested Capital Q/Q Growth		 25.65% -7.57% -61.98% 19.49% -18.95% -23.54% -55.99% 32.64% 45.99% -38.59% -1.20%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -6,564.58% 0.00% 0.00% -37,857.14% -7,957.41% -65,271.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -7,208.33% 0.00% 0.00% -40,071.43% -8,038.89% -65,000.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -6,802.08% 0.00% 0.00% -38,585.71% -8,129.63% -66,471.43% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -6,822.92% 0.00% 0.00% -38,650.00% -8,142.59% -66,585.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.31% 100.20% 100.18% 100.17% 100.16% 100.17% 100.10% 82.26% 100.09% 83.69% 89.33%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -185.84% -159.08% -121.35% -190.08% -326.46% -1,268.61% -110.63% -52.67% -267.59% -91.68% -48.23%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -42.27% 0.00% 0.00% -184.60% -60.47% -955.32% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -42.40% 0.00% 0.00% -184.91% -60.57% -956.97% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -185.84% -159.08% -121.35% -190.08% -326.46% -1,268.61% -110.63% -52.67% -267.59% -91.68% -48.23%
Return on Equity Simple (ROE_SIMPLE)		 -227.98% 0.00% -124.93% -209.54% -423.68% 0.00% -91.55% -29.46% -188.63% 0.00% -32.50%
Net Operating Profit after Tax (NOPAT)		 -2.42 -3.32 -3.21 -3.93 -3.04 -3.19 -4.11 -6.03 -2.90 -3.88 -4.05
NOPAT Margin		 -5,045.83% 0.00% 0.00% -28,050.00% -5,627.22% -45,500.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.27% -14.68% -11.69% -12.97% -17.88% -44.96% -8.68% -2.99% -13.32% -3.13% -2.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 2,785.42% 0.00% 0.00% 13,307.14% 2,274.07% 19,585.71% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 4,522.92% 0.00% 0.00% 26,864.29% 5,864.81% 45,514.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 7,308.33% 0.00% 0.00% 40,171.43% 8,138.89% 65,100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.27 -5.06 -5.08 -5.40 -4.39 -4.65 -5.95 -8.94 -4.28 -5.64 -5.66
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.15 -4.99 -4.98 -5.30 -4.30 -4.57 -5.87 -8.86 -4.19 -5.55 -5.57
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.54 3.29 0.21 0.53 1.25 33.04 0.35 3.86 1.18 1.39 1.51
Price to Tangible Book Value (P/TBV)		 2.54 3.29 0.21 0.53 1.25 33.04 0.35 3.86 1.18 1.39 1.51
Price to Revenue (P/Rev)		 261.38 129.85 41.61 76.72 86.37 88.98 102.63 4,806.94 1,944.33 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 143.16 74.02 0.00 0.00 0.00 55.78 0.00 3,522.60 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.12 -1.04 -1.07 -1.15 -1.24 -2.13 -1.15 -1.05 -1.28 -1.13 -1.08
Leverage Ratio		 1.27 1.19 1.19 1.31 1.49 3.38 1.22 1.07 1.43 1.19 1.11
Compound Leverage Factor		 1.28 1.20 1.20 1.31 1.50 3.39 1.22 0.88 1.43 1.00 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -15.67 -35.25 -11.33 -18.33 -27.93 -55.20 -7.78 53.45 -14.99 3.53 9.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.63 1.90 5.67 4.41 2.35 0.94 5.83 25.48 4.18 10.49 15.01
Quick Ratio		 4.52 1.61 5.49 4.26 2.10 0.64 5.72 25.34 4.13 10.38 14.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.37 -1.90 -1.52 -3.86 -2.30 -2.09 -2.48 -5.18 -2.09 -2.49 -3.90
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% -409,500.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.00 0.00 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 9.73 5.21 24.33 1.70 2.23 2.59 2.68 1.74 0.13 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.19 0.24 0.29 0.30 0.43 0.49 0.61 0.42 0.05 0.00 0.00
Accounts Payable Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 37.50 70.00 15.00 214.88 163.71 141.13 136.27 209.43 2,841.79 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 50,567.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -50,530.21 70.00 15.00 214.88 163.71 141.13 136.27 209.43 2,841.79 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.11 -1.19 -1.93 -1.56 -1.85 -2.29 -3.57 -2.40 -2.66 -3.68 -3.73
Invested Capital Turnover		 -0.07 -0.15 -0.07 -0.04 -0.05 -0.04 -0.03 -0.03 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.05 -1.42 -1.68 -0.06 -0.74 -1.09 -1.64 -0.85 -0.80 -1.39 -0.16
Enterprise Value (EV)		 10 5.40 -14 -5.79 -0.69 4.18 -18 215 -0.55 15 29
Market Capitalization		 19 9.48 3.04 4.76 5.87 6.67 7.70 293 14 65 97
Book Value per Share		 $0.92 $0.35 $1.79 $0.32 $0.17 $0.01 $8.76 $3.27 $4.44 $5.04 $6.08
Tangible Book Value per Share		 $0.92 $0.35 $1.79 $0.32 $0.17 $0.01 $8.76 $3.27 $4.44 $5.04 $6.08
Total Capital		 7.52 2.88 15 8.99 4.71 0.20 22 76 12 47 64
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -8.63 -4.08 -17 -11 -6.57 -2.49 -26 -78 -14 -51 -68
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.70 -1.79 -2.48 -2.07 -2.32 -2.74 -4.00 -2.72 -3.23 -4.18 -4.12
Debt-free Net Working Capital (DFNWC)		 6.93 2.29 14 8.49 4.24 -0.25 22 76 11 47 64
Net Working Capital (NWC)		 6.93 2.29 14 8.49 4.24 -0.25 22 76 11 47 64
Net Nonoperating Expense (NNE)		 0.85 1.75 1.89 1.48 1.36 1.48 1.84 1.33 1.38 0.84 1.01
Net Nonoperating Obligations (NNO)		 -8.63 -4.08 -17 -11 -6.57 -2.49 -26 -78 -14 -51 -68
Total Depreciation and Amortization (D&A)		 0.11 0.06 0.10 0.10 0.09 0.08 0.08 0.08 0.09 0.09 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -2,326.03% -2,449.32% -3,393.15% -3,330.65% -3,416.18% -3,652.00% -5,332.00% -4,460.66% -46,100.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 9,495.89% 3,134.25% 19,273.97% 13,687.10% 6,238.24% -332.00% 29,170.67% 123,973.77% 156,128.57% 0.00% 0.00%
Net Working Capital to Revenue		 9,495.89% 3,134.25% 19,273.97% 13,687.10% 6,238.24% -332.00% 29,170.67% 123,973.77% 156,128.57% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($6.80) ($179.18) ($7.99) ($3.40) ($2.72) ($57.12) ($2.76) ($0.33) ($1.64) ($1.31) ($0.48)
Adjusted Weighted Average Basic Shares Outstanding		 480.69K 28.28K 638.57K 1.62M 1.65M 81.52K 2.16M 22.08M 2.62M 4.06M 10.64M
Adjusted Diluted Earnings per Share		 ($6.80) ($179.18) ($7.99) ($3.40) ($2.72) ($57.12) ($2.76) ($0.33) ($1.64) ($1.31) ($0.48)
Adjusted Weighted Average Diluted Shares Outstanding		 480.69K 28.28K 638.57K 1.62M 1.65M 81.52K 2.16M 22.08M 2.62M 4.06M 10.64M
Adjusted Basic & Diluted Earnings per Share		 ($6.80) ($179.18) $0.00 $0.00 $0.00 ($57.12) $0.00 $0.00 $0.00 ($1.31) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 480.69K 480.69K 1.65M 1.65M 1.65M 149.85K 2.57M 23.45M 9.37M 10.56M 23.22M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.42 -3.32 -3.21 -3.93 -3.04 -3.19 -4.11 -6.03 -2.90 -3.88 -4.05
Normalized NOPAT Margin		 -5,045.83% 0.00% 0.00% -28,050.00% -5,627.22% -45,500.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -6,822.92% 0.00% 0.00% -38,650.00% -8,142.59% -66,585.71% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -9.25% 0.00% -10.24% -9.92% -9.36% -9.55% -14.51% -13.25% -13.66% -27.09% -14.04%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise, investor-focused snapshot of Benitec Biopharma (BNTC) using the last four years of quarterly data. Key themes include liquidity and funding strength, revenue/profitability trends, and balance sheet health.

  • Strong liquidity in latest quarter: Q1 2025 shows Cash & Equivalents of $67,841,000, Total Assets of $68,774,000, Total Liabilities of $4,594,000, and Total Equity of $64,178,000, indicating a debt-free balance sheet with substantial cash backing.
  • Robust financing taps driving liquidity: In late 2024, the company issued Common Equity for $42,999,000 and posted Net Cash From Financing Activities of $40,071,000, contributing to a Net Change in Cash of $36,773,000 in Q4 2024.
  • Debt-free balance sheet trend: Across recent quarters, Total Liabilities remain modest relative to Total Assets, underscoring minimal leverage and lower interest burden.
  • Non-operating income provides some cushion: In Q1 2025, Total Other Income / (Expense), net was $732,000 (Interest & Investment Income $604,000 and Other Income $128,000), helping offset operating losses slightly.
  • Ongoing capital access supports runway: Recurrent capital market activity in 2024–2025 suggests management can fund ongoing R&D and operations if needed.
  • Revenue remains largely non-existent: Operating Revenue and Total Revenue are zero in Q1 2025 and Q4 2024, with limited- or non-existent revenue in several prior quarters, reflecting a pre-revenue stage.
  • Equity dilution signals ongoing shareholder impact: Shares outstanding metrics show substantial dilution potential (weighted average shares and common equity levels vary widely, with EPS remaining negative in recent quarters), which may affect per-share value.
  • Persistent net losses and operating cash burn: Net income in Q1 2025 is -$5.059 million; similar losses appear in other quarters (e.g., Q4 2024 -$4.72M, Q3 2024 -$4.28M). Operating cash flow is negative in multiple quarters (e.g., Q1 2025 OCF -$4.586 million, Q3 2024 OCF -$6.168 million, Q2 2024 OCF -$5.365 million).
  • Reliance on financing for funding: The company’s need to raise capital to fund operations raises questions about sustainability if financing conditions tighten, given ongoing cash burn from operations.
05/21/26 02:49 PM ETAI Generated. May Contain Errors.

Benitec Biopharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Benitec Biopharma's financial year ends in June. Their financial year 2024 ended on June 30, 2024.

Benitec Biopharma's net income appears to be on an upward trend, with a most recent value of -$21.75 million in 2024, rising from -$18.21 million in 2022. The previous period was -$19.56 million in 2023. View Benitec Biopharma's forecast to see where analysts expect Benitec Biopharma to go next.

Benitec Biopharma's total operating income in 2024 was -$22.49 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $22.49 million

Over the last 2 years, Benitec Biopharma's total revenue changed from $73 thousand in 2022 to $0.00 in 2024, a change of -100.0%.

Benitec Biopharma's total liabilities were at $4.96 million at the end of 2024, a 16.4% increase from 2023, and a 60.5% increase since 2022.

In the past 2 years, Benitec Biopharma's cash and equivalents has ranged from $2.48 million in 2023 to $50.87 million in 2024, and is currently $50.87 million as of their latest financial filing in 2024.

Over the last 2 years, Benitec Biopharma's book value per share changed from 0.35 in 2022 to 5.04 in 2024, a change of 1,330.1%.


Related Companies

Financial statements for NASDAQ:BNTC last updated on 4/7/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel